Skip to main content

Market Overview

BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder


BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry (fosdenopterin) Injection to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A.

  • MoCD is a rare metabolic disorder characterized by severe and rapidly progressive neurologic damage caused by the functional loss of sulfite oxidase, 1 of 4 molybdenum-dependent enzymes. 
  • The condition is characterized by seizures, feeding difficulties, and encephalopathy (brain damage).
  • Nulibry is BridgeBio's first FDA-approved therapeutic, and the company says it is a first-in-class approved cPMP substrate replacement therapy.
  • The treatment was reviewed under Priority Review and received FDA Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease Designations.
  • Price Action: BBIO shares closed 8.5% higher at 70.68 on Friday.

Related Articles (BBIO)

View Comments and Join the Discussion!

Posted-In: molybdenum cofactor deficiency Orphan Drug DesignationBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at